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Abstract 
 
Hepatitis E Virus is a causative agent of hepatitis. Viral E hepatitis is responsible for various 
clinical manifestations. However, immune reactions due to hepatitis E virus are rarely 
encountered. A case of membranoproliferative glomerulonephritis associated with hepatitis E 
virus is reported her.  
 
 
Introduction 
 
 
Viral Hepatitis is a major public health problem worldwide. The hepatitis is a disease that can be 
caused by five unrelated human viruses, namely, hepatitis A virus (HAV), hepatitis B virus 
(HBV), hepatitis C virus (HCV), hepatitis D (HDV) and hepatitis E (HEV). Table 1 summarizes 
the outcome of the different viruses. Hepatitis E was not recognized as distinct clinical entity 
until 1980, previously known as enterically transmitted non-A, non-B hepatitis (NANBH). 
Hepatitis E is caused by infection with the hepatitis E Virus, a non-enveloped single-stranded, 
linear, positive sense, polyadenenylated RNA (7,5kb). Structural and physiochemical properties, 
the hepatitis E virus have been classified in the family Caliciviridae, genus Calicivirus. The 
hepatitis E virus is seen in epidemic outbreak in regions where low standards of sanitation 
promote the transmission of the virus. Epidemics of hepatitis E have been reported in Southern 
and Central asia, North and West Africa, Middle East, an in parts of Mexico. It is also seen as 
sporadic disease in many parts of the world often in travellers returning from abroad. The 
incubation period following exposure to hepatitis E virus range for 2 to 10 weeks. It is a self –
limiting disease followed by recovery and typically lasts 1-4 weeks, chronic infection was until 
recently thought not to occur. Typical signs and symptom of hepatitis include jaundice, anorexia, 
hepatomegaly, abdominal pain and tenderness, fever, mild chills, nausea, vomiting, clay-
coloured stools, dark coloured urine, diarrhoea, arthralgia, although the disease may range in 
severity from sub clinical to fulminant form with overall patient population mortality rates 
ranging between 0,5-4%, and as 10-40% among pregnant women. During outbreaks the infection 
is most common among adults aged 15-40 years (3-30%) than among children (0,2-10%). 
Hepatitis B and C Virus infection is associated with membranoproliferative glomerulonephritis. 
Membranoproliferative glomerulonephritis is a kidney disorder that may be related to immune 
system function. There has only once, been reported membranoproliferative glomerulonephritis 
due to acute hepatitis E virus. We report a patient with acute hepatitis E virus that developed 
membranoproliferative glomerulonephritis. 
 
 
Case Report 
 
A 25 year old man was admitted to Ullevål University Hospital on marsh 14, 2008, with a thirty 
day history of mild diarrhoea and 10 days dark urine, on control 3 days later the patient had 
fever, loss of appetite, nausea, vomiting and upper abdominal pain. He was of Arabic origin, 
lived in Norway and with recently travel history to an endemic area within six to eight weeks 
prior to symptom onset. The patient had a non-organised individual travel to India and Nepal in 
December, January and February, the length of his stay ranged 9 weeks. The patient had been 
healthy during the travel, however 1 week prior to departure, after staying three days along the 
Varanasi River in North-India, the patient had a history of reported vomiting and flu-like 
syndrome, cough, low grade fever and night sweats, this condition lasted for three days. The 
patient was hepatitis A and hepatitis B vaccinated.  
 
Physical examination revealed splenomegaly, tenderness in the right hypochondrium, and sever 
jaundice. Abnormal laboratory findings included an International Normalized Ratio (INR) at 2.1.  
Liver dysfunction was seen, with an increase in levels of aspartate aminotransferase (5665 U/L),  
alanine aminotransferase (6959 U/L), lactate dehydrogenase (617 U/L), alkaline phosphatase 
(363 U/L), glutamyltransferase and total bilirubin (468 umol/l). Serum immunoglobulinG levels 
were relatively elevated (15,3 g/L). No antibodies against human immunodeficiency virus (HIV), 
hepatitis C virus (HCV), hepatitis B virus (HBV), Cytomegalovirus (CMV), Epstein Barr Virus 
(EBV) were not detected, instead Anti-HEV IgG was detected with Genelabs Diagnostics HEV 
Elisa. Antibodies against smooth muscle (SMA) were detected, and SMA titer reveled 64, 
however ANA ELISA, AMA, Anti-LKM1, RF, IgA RF ELISA, IgM RF ELISA, Anti-CCP, C-
ANCA screen, P-ANCA screen, Anti-PR3, Anti-MPO where all negative. Chest X-ray was 
normal. Abdominal ultrasonography taken 18.03.08, showed hepatomegaly, no thickened 
gallbladder and splenomegaly. The kidney basement membrane showed no pathology. The 
patient was treated conservatively.  
 
On the twentieth day the patient improved considerably. His liver function test showed serum 
aspartate aminotransferase (143 U/L), alanine aminotransferase (522 U/L) and bilirubin (94 
umol/l). However the patient started to describe the manifestation of kidney pain (severe back 
ache). Ibux medical treatment relieved immediately the symptoms of kidney pain. Urine 
Microbiological Bacterial Cultures revealed no bacterial nephritis. A new abdominal 
utrasonography taken 01.04.08 demonstrated normal sized kidneys with widespread thickening 
of the kidney basement membrane, compatible with renal membranoproliferative 
glomerulonephritis. A renal biopsy was not performed. The patient’s initial urinalysis was 
positive for blood and leukocytes. Dipstick urinanalysis revealed blood ++++, and leukocytes 
+(+), Urine light microscope provided further confirmation of haematuria and leukocytes. He 
had no hypertension and no decline in renal function. Full blood count revealed no other than 
hepatitis E virus infection. 
 
He was discharged from hospital, followed up, and received no other medication than Ibux. 
During follow up of six months, the patient kept well and liver function, kidney function test 
where normal. 
 
Discussion 
 
 
Most autochthonous hepatitis E virus infections are selflimiting, acute icteric hepatitis; however, 
follow-up studies of 40 hepatitis E virus infected patients demonstrated that six (15 %) patients 
developed complications. The clinical features of autochthonous hepatitis E infection range from 
asymptomatic infection to mild hepatitis, to subacute liver failure. Study based on affected 
individuals have presented a range of other non-hepatic symptoms, however this studies have not 
yet reviled infected patient with acute hepatitis E virus, that develop membranoproliferative 
glomerulonephritis Glomerulonephritis. Although one of the most frequent kidney diseases 
associated with chronic hepatitis C virus (HCV) and B virus is membranoproliferative 
glomerulonephritis. Membranoproliferative glomerulonephritis due to hepatitis virus is still a 
poorly understood disease. To our knowledge Hepatitis E Virus causing membranoproliferative 
glomerulonephritis, has only once been reported in a case report. Many associated infections 
have been reported to cause membranoproliferative glomerulonephritis, but none have been 
found in this patient. It is believed that the persistent infection with the hepatitis E virus (HEV) is 
responsible for an immune complex-mediated glomerulonephritis in this patient. Development of 
membranoproliferative glomerulonephritis in this patient with clinical hepatitis and positive 
serology for Anti-HEV IgG makes the cause and effect relationships of membranoproliferative 
glomerulonephritis with hepatitis E most likely. 
 
The principal clinical manifestations of glomerulus’s disease in hepatitis virus infected patients 
are the presence of proteinuria and microscopic haematuria with or without impaired kidney 
function, this patient had also demonstrated widespread thickening of the kidney basement 
membrane. 
 
The clinical manifestations of membranoproliferative glomerulonephritis may be so variable that 
the disease is often diagnosed only if it has been systematically considered. Many times, it is 
diagnosed as a form of back pain. In a UK hospital-based study, 40patient with autochthonous 
hepatitis E were identified, with affected individuals presenting a range of other non-specific 
symptoms, 2% describe the manifestation of back pain. 
 
 
 
 
Conclusion 
 
 
Many cases of glomerulonephritis result in a mild, asymptomatic illness that remains 
undiagnosed.  
 
Because hepatitis E virus has now been pathogenetically linked to glomerulonephritis in this 
patient, testing for this virus should be considered in the serologic work-up of patients with 
glomerulonephritis, particularly in countries with a high prevalence of hepatitis E virus, or 
patients with resent travel history to hepatitis E virus endemic countries. 
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